News:
COVID: BioNTech to pay $1.2 billion over vaccine royalties - COVID: BioNTech to pay $1.2 billion over vaccine royalties - Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25% - Moderna wins Covid jab patent dispute over Pfizer and BioNTech
BioNTech
Bookmark
ShareKey facts
- city: Mainz
- country: Germany
- sector: Health Care
- foundation year: 2008
- industry: Biotechnology
- CEO: Prof. Ugur Sahin M.D.
Classified as: organization
Summary
BioNTech is a company. It is located in Mainz, Germany and was founded in 2008. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business
BioNTech is one of the companies in Germany, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 15.9B $
- Debt: 186.6M $
- Employees: 3,082 people
- Free cash flow: 2.9B $
- Market cap: 35.9B $
- Profits: 10.3B $
- Revenues: 23.4B $
Stocks from BioNTech
Explore more on business
Talking Points:
- Wir führen Sie durch die spannende Welt der Immuntherapien. Hier finden Sie Informationen zur Grundlagenforschung und zu neuartigen Behandlungsmöglichkeiten.
- Our vision is to harness the power of the immune system to develop novel therapies based on groundbreaking R&D with cutting-edge technologies $BNTX
- Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. | At BioNTech we understand that every cancer patient's tumor is unique and therefore each patient's treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ...
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Learn more about talking points